Amoxicillin from China on Complaint of
AuroPharma under Anti-dumping Net
[Anti-dumping Initiation Notification
No.14/06/2015-DGAD dated 27th April 2016]
Subject: Anti-dumping investigation
concerning imports of ‘Amoxicillin’, originating in or exported from China PR.
M/s Aurobindo Pharma Limited
(hereinafter referred to as the applicant/ domestic industry) have filed an
application before the Designated Authority (hereinafter also referred to as
the Authority) in accordance with the Customs Tariff Act, 1975 as amended from
time to time (hereinafter also referred to as the Act) and Customs Tariff
(Identification, Assessment and Collection of Anti-Dumping Duty on Dumped
articles and for Determination of injury) Rules, 1995 as amended from time to
time (hereinafter also referred to as the Rules) for initiation of anti-dumping
investigation and imposition of anti dumping duty concerning imports of
Amoxicillin (hereinafter also referred to as the subject goods), originating in
or exported from China PR (hereinafter also referred to as the subject
country).
2. And
whereas, the Authority prima facie finds that sufficient evidence of dumping of
the subject goods, originating in or exported from the subject countries,
‘injury’ to the domestic industry and causal link between the alleged dumping
and ‘injury’ exist to justify initiation of an anti-dumping investigation; the
Authority hereby initiates an investigation into the alleged dumping, and
consequent injury to the domestic industry in terms of Rule 5 of the Rules, to
determine the existence, degree and effect of alleged dumping and to recommend
the amount of antidumping duty, which if levied, would be adequate to remove
the ‘injury’ to the domestic industry.
Domestic Industry & Standing
3. The
Application has been filed by M/s Aurobindo Pharma Limited as the domestic
industry.
4. As
per the evidence available on record, the production of the applicant company
constitutes “a major proportion” of the domestic production. The Authority,
therefore, determines that the applicant company constitutes eligible domestic
industry within the meaning of Rule 2 (b) of the Anti Dumping Rules and the
application satisfies the criteria of standing in terms of Rule 5 (3) of the
Rules supra.
Product under consideration
5. The
product under consideration in the investigation is “Amoxycillin”.
6. The
product under consideration is also known as Amoxicillin Trihydrate.
Amoxicillin Trihydrate is a semi synthetic antibiotic, an analog of ampicillin, with a broad spectrum of bactericidal
activity against many Gram-positive and Gram-negative microorganisms.
7. Amoxicillin
is used to reduce the development of drug-resistant bacteria. To maintain the
effectiveness of Amoxicillin and other antibacterial drugs, Amoxicillin should
be used only to treat infections that are proven or strongly suspected to be
caused by bacteria.
8. Amoxicillin
being an organic chemical is categorized under Chapter 29 of the Customs Tariff
Act under subheading 29411030. The Customs classification is, however,
indicative only and in no way binding on the scope of the proposed
investigation and proposed measures.
Like Article
9. The
applicant has claimed that there is no known difference between the subject
goods exported from subject countries and that produced by the domestic
industry. As submitted by the applicant, the product under consideration
produced by the domestic industry and imported from subject country are
comparable in terms of essential product characteristics such as physical &
chemical characteristics, manufacturing process & technology, functions
& uses, product specifications, pricing, distribution & marketing and
tariff classification of the goods. Consumers can use and are using the two
interchangeably. The applicants have further claimed that two are technically
and commercially substitutable and, hence, should be treated as ‘like article’
under the Rules. Therefore, for the purpose of the present investigation, the
Authority treats the subject goods produced by the applicant in India as ‘Like
Article’ to the subject goods being imported from the subject country.
Countries involved
10. The
present investigation is in respect of alleged dumping of the product under
consideration from China PR.
Normal Value
11. The
Applicant has claimed that China PR should be treated as a non-market economy
country and its normal value be determined in accordance with Para 7 and 8 of
Annexure I of the Rules. The applicant has claimed normal value for China PR on
the basis of cost of production in India, duly adjusted. In terms of Para 8 in
Annexure 1 to the Rules it is presumed that the producers of the subject goods
in China PR are operating under non market economy conditions. In view of the
above non-market economy presumption and subject to rebuttal of the same by the
responding exporters from China PR, normal value of the subject goods in China
PR has been estimated in terms of Para 7 of Annexure 1 to the Rules.
Export Price
12. The
export price has been claimed by the applicant as the weighted average import
price from subject country based on the transaction-wise import data obtained
from the DGCI&S. Price adjustments have been made on account of ocean
freight, marine insurance, commission, inland freight expenses, port expenses
and VAT to arrive at the net export price.
Dumping Margin
13. The
normal value has been compared with the export price at ex-factory level. There
is sufficient prima facie evidence that the normal value of the subject goods
in the subject country is higher than the ex-factory export price, indicating,
that the subject goods are being dumped into the Indian market by the exporters
from the subject country. The dumping margin is estimated to be above de
minimis.
Injury and Causal Link
14. Information
furnished by the applicant has been considered for assessment of injury to the
domestic industry. The applicant has furnished evidence regarding the injury
having taken place as a result of the alleged dumping in the form of increased
volume of dumped imports in absolute terms and in relation to production and
consumption, price undercutting, price underselling and consequent significant
adverse impact in terms of decline in production, sales, market share,
inventories. There is sufficient prima facie evidence of the ‘material injury’
being suffered by the domestic industry caused by dumped imports from subject
country to justify initiation of an antidumping investigation.
15. The
applicant has claimed that imports have spurted from China PR. The Applicant
has therefore, claimed that the imports are threatening material injury to the
domestic industry. The Applicant has submitted that there is significant
increase in imports, decline in import price, significant surplus capacity and
high export orientation of the producers in subject country as grounds for
claiming threat of material injury to the domestic industry from subject
imports.
Period of Investigation (POI)
16. The
Period of Investigation (POI) proposed by the applicant is from 1st October
2014 to 30th September 2015 and the injury investigation period is for the
periods, Apr’12-Mar’13, Apr’13-Mar’14, Apr’14-Mar’15 and the Period of
Investigation. However, for enabling the Authority to make required analysis on
the basis of more updated data, the Authority hereby determines the POI as 1st
October 2014 to 31st December 2015 (15 Months). The injury investigation period
will however, cover the periods 2012-13, 2013-14, 2014-15 and POI.
Submission of information
17. The
known exporters in the subject country, the Government of the subject countries
through their embassy in India, the importers and users in India known to be
concerned with the product are being addressed separately to submit relevant
information in the form and manner prescribed and to make their views known to
the Authority at the following address:
The Designated Authority,
Directorate General of Anti-Dumping & Allied Duties,
Ministry of Commerce & Industry, Department of Commerce
4th Floor, Jeevan Tara Building, 5 Parliament Street,
New Delhi -110001.
18. Any
other interested party may also make its submissions relevant to the
investigation in the prescribed form and manner within the time limit set out
below.
Time limit
19. Any
information relating to the present investigation and any request for hearing
should be sent in writing so as to reach the Authority at the address mentioned
above not later than forty days (40 Days) from the date of publication of this
Notification. If no information is received within the prescribed time limit or
the information received is incomplete, the Authority may record its findings
on the basis of the facts available on record in accordance with the
Anti-dumping Rules.
20. All
the interested parties are hereby advised to intimate their interest (including
the nature of interest) in the instant matter and file their questionnaire
responses and offer their comments to the domestic industry’s application
regarding the need to continue or otherwise the Antidumping measures within 40
days from the date of initiation of this investigation.
Submission of Information on
Non-Confidential basis
21. In
case confidentiality is claimed on any part of the questionnaire’s
response/submissions, the same must be submitted in two separate sets (a)
marked as Confidential (with title, index, number of pages, etc.) and (b) other
set marked as Non Confidential (with title, index, number of pages, etc.). All
the information supplied must be clearly marked as either “confidential” or
“non-confidential” at the top of each page.
22. Information
supplied without any confidential marking shall be treated as nonconfidential
and the Authority shall be at liberty to allow the other interested parties to
inspect any such non-confidential information. Two (2) copies of the
confidential version and five (05) copies of the non confidential version must
be submitted by all the interested parties.
23. For
information claimed as confidential; the supplier of the information is
required to provide a good cause statement along with the supplied information
as to why such information cannot be disclosed and/or why summarization of such
information is not possible.
24. The
non-confidential version is required to be a replica of the confidential
version with the confidential information preferably indexed or blanked out
/summarized depending upon the information on which confidentiality is claimed.
The non-confidential summary must be in sufficient detail to permit a
reasonable understanding of the substance of the information furnished on
confidential basis. However, in exceptional circumstances, parties submitting
the confidential information may indicate that such information is not
susceptible to summarization; a statement of reasons why summarization is not
possible must be provided to the satisfaction of the Authority.
25. The
Authority may accept or reject the request for confidentiality on examination
of the nature of the information submitted. If the Authority is satisfied that
the request for confidentiality is not warranted or the supplier of the
information is either unwilling to make the information public or to authorize
its disclosure in generalized or summary form, it may disregard such
information.
26. Any
submission made without a meaningful non-confidential version thereof or
without a good cause statement on the confidentiality claim may not be taken on
record by the Authority. The Authority on being satisfied and accepting the
need for confidentiality of the information provided; shall not disclose it to
any party without specific authorization of the party providing such
information.
Inspection of Public File
27. In
terms of rule 6(7) any interested party may inspect the public file containing
nonconfidential versions of the evidence submitted by other interested parties.
Non-cooperation
28. In
case any interested party refuses access to and otherwise does not provide
necessary information within a reasonable period, or significantly impedes the
investigation, the Authority may declare such interested party as
non-cooperative and record its findings on the basis of the facts available to
it and make such recommendations to the Central Government as deemed fit.